A Comparative Study of Efficacy and Safety of Oral Tranexamic Acid Versus Topical Tranexamic Acid Combined with Microneedling in Treatment of Melasma
Keywords:
Melasma, Tranexamic Acid, Microneedling, MASI Score, HyperpigmentationAbstract
Background: Melasma is a chronic acquired pigmentary disorder characterized by symmetrical hyperpigmented macules over sun-exposed areas, particularly the face. It has a multifactorial etiology involving hormonal influences, ultraviolet radiation, and genetic predisposition. Tranexamic acid has emerged as a promising therapeutic option due to its anti-plasmin and anti-melanogenic effects.
Aim: To compare the efficacy and safety of oral tranexamic acid with topical tranexamic acid combined with microneedling in patients with melasma.
Methods: This randomized controlled study included a total of 78 patients clinically diagnosed with Melasma, who were equally divided into two groups of 39 patients each. Group 1 received oral Tranexamic acid at a dose of 250 mg twice daily, whereas Group 2 was treated with topical 4% tranexamic acid applied in combination with microneedling procedures performed at two-week intervals. The duration of treatment for both groups was 12 weeks, and all patients were followed up for a total period of 24 weeks to assess treatment response and recurrence. The efficacy of treatment was evaluated using standardized assessment tools, including the Melasma Area and Severity Index (MASI) score and the Physician Global Assessment (PGA), while safety was assessed by monitoring adverse effects throughout the study period, and appropriate statistical analysis was performed to compare outcomes between the two groups.
Results: The baseline demographic and clinical characteristics were comparable between the two groups, with no statistically significant difference observed (p > 0.05), indicating uniformity at baseline. Both groups showed significant improvement in MASI scores over time, demonstrating the effectiveness of both treatment modalities in managing Melasma; however, Group 1, which received oral Tranexamic acid, exhibited a superior reduction in MASI scores compared to Group 2. At 12 weeks, the reduction was 57.44% in Group 1 versus 49.65% in Group 2, which further increased at 18 weeks to 71.08% and 64.05%, respectively, and was maintained at 24 weeks with reductions of 67.78% in Group 1 and 59.51% in Group 2, showing a statistically significant difference (p < 0.001). In terms of safety, Group 1 was associated with systemic adverse effects such as nausea, abdominal discomfort, and oligomenorrhoea, whereas Group 2 showed a higher incidence of local adverse effects including erythema, pain, edema, burning sensation, and post-inflammatory hyperpigmentation (PIH).
Conclusion: Oral Tranexamic acid is more effective in reducing the severity of Melasma compared to topical tranexamic acid combined with microneedling, with greater and sustained MASI score reduction. However, oral therapy was associated with mild systemic adverse effects, while the topical approach showed more local side effects. The choice should be individualized based on efficacy, safety and patient profile.
References
Handel AC, Miot LDB, Miot HA. Melasma: a clinical and epidemiological review. An Bras Dermatol. 2014 Sep-Oct;89(5):771–82.
Sarkar R, Chugh S, Garg VK. Newer and upcoming therapies for melasma. Indian J Dermatol Venereol Leprol. 2012 Jul-Aug;78(4):417–28.
Pichardo R, Vallejos Q, Feldman SR, Schulz MR, Verma A, Quandt SA, et al. The prevalence of melasma and its association with quality of life in adult male Latino migrant workers. Int J Dermatol. 2009 Jan;48(1):22–6.
Mahmoud BH, Ruvolo E, Hexsel CL, Liu Y, Owen MR, Kollias N, et al. Impact of long-wavelength UVA and visible light on melanocompetent skin. J Invest Dermatol. 2010 Aug;130 (8):2092–7.
Ogbechie-Godec OA, Elbuluk N. Melasma: an up-to-date comprehensive review. Dermatol Ther (Heidelb). 2017 Sep;7(3):305–18.
Kang HY, Suzuki I, Lee DJ, Ha J, Reiniche P, Aubert J, et al. Transcriptional profiling shows altered expression of Wnt pathway-related genes in melasma. J Invest Dermatol. 2011 Aug;131(8):1692–700.
Bandyopadhyay D. Topical treatment of melasma. Indian J Dermatol. 2009 Oct-Dec;54(4):303–9.
Werlinger KD, Guevara IL, González CM, Rincón ET, Caetano R, Haley RW, et al. Prevalence of melasma among premenopausal women. Arch Dermatol. 2007 Mar;143(3):424–5.
Ibrahim Mohamed N, Hegab DS, El Maghraby GM, El-Ashmawy AA. Efficacy and safety of topical tranexamic acid with microneedling in melasma. Dermatol Pract Concept. 2023 Jul;13(3):e2023195.
Khurana VK, Sarkar R, Garg VK. Oral tranexamic acid in melasma: a comparative study. J Clin Aesthet Dermatol. 2018;11(5):28–33.
Panchal V, Chaudhary S, Patel R. Efficacy of oral versus topical tranexamic acid in melasma: a systematic review and meta-analysis. Dermatol Ther. 2023;36(2):e15789.
Pazyar N, Feily A, Yaghoobi R. Comparison of tranexamic acid and vitamin C in melasma treatment. J Cosmet Dermatol. 2023;22(4):1105–10.
Batra J, Brar BK, Kumar S, Arora H. Tranexamic acid in melasma: comparative evaluation of oral versus transepidermal administration. J Cutan Aesthet Surg. 2022 Oct-Dec;15(4):394–9.
Dawaud MSK, Hegab DS, Mohamed EMG, El-Ashmawy AA. Topical tranexamic acid with microneedling versus laser in melasma. Dermatol Pract Concept. 2023 Jul;13(3):e2023195.
Sarkar R, Gokhale N, Godse K, Ailawadi P, Arya L, Sarma N, et al. Medical management of melasma: consensus recommendations. Indian J Dermatol. 2017 Nov-Dec;62(6):558–77.
Agrawal M, Varma K, Kumar U, Bhargava S, Mahadik A, Agrawal V. Comparison of oral versus topical tranexamic acid for melasma. IP Indian J Clin Exp Dermatol. 2023;9(2):84–89.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Dr. Moni Kashyap et al

This work is licensed under a Creative Commons Attribution 4.0 International License.



